APA (7th ed.) Citation

CJ, V., SK, K., T, M., M, M., R, M., S, H., . . . G, M. (2023). A Phase 3b Study for Management of Ocular Side Effects in Patients with Epidermal Growth Factor Receptor-Amplified Glioblastoma Receiving Depatuxizumab Mafodotin. Ophthalmic research, 66(1), 1030. https://doi.org/10.1159/000531142

Chicago Style (17th ed.) Citation

CJ, Vize, et al. "A Phase 3b Study for Management of Ocular Side Effects in Patients with Epidermal Growth Factor Receptor-Amplified Glioblastoma Receiving Depatuxizumab Mafodotin." Ophthalmic Research 66, no. 1 (2023): 1030. https://doi.org/10.1159/000531142.

MLA (9th ed.) Citation

CJ, Vize, et al. "A Phase 3b Study for Management of Ocular Side Effects in Patients with Epidermal Growth Factor Receptor-Amplified Glioblastoma Receiving Depatuxizumab Mafodotin." Ophthalmic Research, vol. 66, no. 1, 2023, p. 1030, https://doi.org/10.1159/000531142.